Get notified of page updates
Enroll in Research > Research Search & Enroll Tool > Phase 1 Study of Oral Drug PMD-026 in People With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer
Printer Friendly Page Phase 1 Study of Oral Drug PMD-026 in People With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer

Phase 1 Study of Oral Drug PMD-026 in People With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer

Clinicaltrials.gov identifier:
NCT04115306


Study Contact Information:

For more information about the study, visit https://phoenixmd.ca/clinical-trials.

Phase 1/1b Study of Oral Drug PMD-026 in People with Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer

About the Study

PMD-026 is a study for people who have been diagnosed with triple negative breast cancer (mTNBC) who have no further treatment options. This research study is investigating if a study drug called PMD-026 is safe and effective for patients with mTNBC.  NOTE: This study is no longer enrolling. 

 

This Study is Open To:

NOTE: This study is no longer enrolling. 

This Study is Not Open To:

NOTE: This study is no longer enrolling.